Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe

Zacks Equity Research
·3-min read

On Jun 29, we issued an updated research report on Bio-Rad Laboratories, Inc. BIO. The company’s solid prospects in the blood-typing market make us optimistic while its shrinking gross margin is a concern. The stock currently carries a Zacks Rank #3 (Hold).

This California-based manufacturer and global supplier of clinical diagnostics and life-science research products has been outperforming its industry for the past six months. The stock has gained 17% against the industry’s 12% decline.

In the first quarter of 2020, Bio-Rad witnessed solid revenue growth at both operating segments. Further, strength in many of its key product lines across major geographic regions buoyed optimism.

The uptick in core polymerase chain reaction (PCR) and Droplet Digital PCR product revenues resulted from robust demand due to coronavirus testing and related research. Further, the FDA’s emergency use authorization (EUA) for the Droplet Digital PCR COVID-19 test kit was encouraging.

Partnerships and collaborations in the time of the pandemic seem strategic for the company. It announced in March that it is providing Real-Time qPCR products to testing laboratories worldwide to screen COVID-19.

BioRad Laboratories, Inc. Price

BioRad Laboratories, Inc. Price
BioRad Laboratories, Inc. Price

BioRad Laboratories, Inc. price | BioRad Laboratories, Inc. Quote

Expansion of the company’s adjusted operating margin instills optimism. Strong solvency with slight leverage, solid prospects in blood typing market and focus on international markets are other positives.

On the flip side, escalating costs and expenses are putting pressure on the bottom line. Also, foreign-exchange woes and operation in a highly competitive market raise concern.

Global macroeconomic woes stemming from the coronavirus pandemic are also concerns.

Key Picks

Some better-ranked stocks from the broader medical space are Quest Diagnostics Incorporated DGX, Hologic, Inc. HOLX and QIAGEN N.V. QGEN.

Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Hologic’s long-term earnings growth rate is estimated at 7%. The company presently has a Zacks Rank #2.

QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
BioRad Laboratories, Inc. (BIO) : Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research